PMC:7074432 / 5674-5943 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"200","span":{"begin":50,"end":54},"obj":"Gene"},{"id":"202","span":{"begin":58,"end":69},"obj":"Chemical"},{"id":"206","span":{"begin":184,"end":211},"obj":"Gene"},{"id":"207","span":{"begin":249,"end":263},"obj":"Chemical"}],"attributes":[{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"Gene:3569"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"MESH:C502936"},{"id":"A206","pred":"tao:has_database_id","subj":"206","obj":"Gene:7124"},{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"MESH:D010431"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T214","span":{"begin":177,"end":182},"obj":"SO:0000646"},{"id":"T213","span":{"begin":184,"end":211},"obj":"PR:000000134"},{"id":"T212","span":{"begin":212,"end":222},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T211","span":{"begin":237,"end":247},"obj":"GO:0042571"},{"id":"T210","span":{"begin":249,"end":263},"obj":"CHEBI:7986;CHEBI:7986"},{"id":"T197","span":{"begin":50,"end":54},"obj":"PR:000001393"},{"id":"T196","span":{"begin":58,"end":69},"obj":"DG_35"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T28","span":{"begin":184,"end":189},"obj":"Disease"}],"attributes":[{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":184,"end":211},"obj":"http://purl.obolibrary.org/obo/PR_000000134"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T67","span":{"begin":50,"end":52},"obj":"Chemical"},{"id":"T69","span":{"begin":58,"end":69},"obj":"Chemical"},{"id":"T70","span":{"begin":206,"end":211},"obj":"Chemical"},{"id":"T71","span":{"begin":212,"end":222},"obj":"Chemical"}],"attributes":[{"id":"A67","pred":"chebi_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A68","pred":"chebi_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A69","pred":"chebi_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A71","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T4","span":{"begin":190,"end":198},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T5","span":{"begin":190,"end":198},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T6","span":{"begin":190,"end":198},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T7","span":{"begin":190,"end":198},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}

{"project":"LitCovid-sentences","denotations":[{"id":"T33","span":{"begin":77,"end":92},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":184,"end":189},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}

{"project":"2_test","denotations":[{"id":"32201439-32035018-47219425","span":{"begin":72,"end":74},"obj":"32035018"},{"id":"T13267","span":{"begin":72,"end":74},"obj":"32035018"}],"text":"y theoretically prove useful (e.g., inhibition of IL-6 by tocilizumab).[24]\n\nOther Therapies\nOther treatment options, which are either used rarely or in experimental state, are SiRNA, tumor necrosis factor-alpha inhibitors, neutralizing antibodies, pentoxifylline, etc."}